Recombination activating genes (RAG) in lymphoma development

Cell Cycle

Volumn 5, Issue 9, 2006, Pages 913-916

  Haines, Brian B ^a   Chun, Jeih Ryu ^b   Chen, Jianzhu ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

Double strand DNA break; Lymphomagenesis; p53; Recombination activating gene (RAG)

Indexed keywords

MICRORNA; NUCLEIC ACID BINDING PROTEIN; PROTEIN RAG; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

B LYMPHOCYTE; CELL MATURATION; DNA RECOMBINATION; IN VIVO STUDY; LYMPHOMA; ONCOGENE; REVIEW; T LYMPHOCYTE;

EID: 33646406328     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.5.9.2732     Document Type: Review

References (54)

1. Schatz DG. V(D)J recombination. Immunol Rev 2004; 200:5-11.
2. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 1992; 68:869-77.
3. Ahnesorg P, Smith P, Jackson SP. XLF interacts with the XRCC4-DNA ligase IV complex to promote DNA nonhomologous end-joining. Cell 2006; 124:301-13.
4. Rooney S, Chaudhuri J, Alt FW. The role of the non-homologous end-joining pathway in lymphocyte development. Immunol Rev 2004; 200:115-31.
5. Dudley EC, Petrie HT, Shah LM, Owen MJ, Hayday AC. T cell receptor beta chain gene rearrangement and selection during thymocyte development in adult mice. Immunity 1994; 1:83-93.
6. Godfrey DI, Kennedy J, Mombaerts P, Tonegawa S, Zlotnik A. Onset of TCR-beta gene rearrangement and role of TCR-beta expression during CD3-CD4-CD8- thymocyte differentiation. J Immunol 1994; 152:4783-92.
7. Aifantis I, Mandal M, Sawai K, Ferrando A, Vilimas T. Regulation of T-cell progenitor survival and cell-cycle entry by the pre-T-cell receptor. Immunol Rev 2006; 209:159-69.
8. Kruisbeek AM, Haks MC, Carleton M, Michie AM, Zuniga-Pflucker JC, Wiest DL. Branching out to gain control: How the pre-TCR is linked to multiple functions. Immunol Today 2000; 21:637-44.
9. Lee J, Desiderio S. Cyclin A/CDK2 regulates V(D)J recombination by coordinating RAG-2 accumulation and DNA repair. Immunity 1999; 11:771-81.
10. Sleckman BP, Bassing CH, Bardon CG, Okada A, Khor B, Bories JC, Monroe R, Alt FW. Accessibility control of variable region gene assembly during T-cell development. Immunol Rev 1998; 165:121-30.
11. Bassing CH, Alt FW. The cellular response to general and programmed DNA double strand breaks. DNA Repair (Amst) 2004; 3:781-96.
12. Difilippantonio MJ, Petersen S, Chen HT, Johnson R, Jasin M, Kanaar R, Ried T, Nussenzweig A. Evidence for replicative repair of DNA double-strand breaks leading to oncogenic translocation and gene amplification. J Exp Med 2002; 196:469-80.
13. Khanna KK, Jackson SP. DNA double-strand breaks: Signaling, repair and the cancer connection. Nat Genet 2001; 27:247-54.
14. Cowell LG, Davila M, Yang K, Kepler TB, Kelsoe G. Prospective estimation of recombination signal efficiency and identification of functional cryptic signals in the genome by statistical modeling. J Exp Med 2003; 197:207-20.
15. Marculescu R, Le T, Simon P, Jaeger U, Nadel B. V(D)J-mediated translocations in lymphoid neoplasms: A functional assessment of genomic instability by cryptic sites. J Exp Med 2002; 195:85-98,
16. Raghavan SC, Swanson PC, Ma Y, Lieber MR. Double-strand break formation by the RAG complex at the bcl-2 major breakpoint region and at other non-B DNA structures in vitro. Mol Cell Biol 2005; 25:5904-19.
17. Raghavan SC, Swanson PC, Wu X, Hsieh CL, Lieber MR. A non-B-DNA structure at the Bcl-2 major breakpoint region is cleaved by the RAG complex. Nature 2004; 428:88-93.
18. Wiemels JL, Leonard BC, Wang Y, Segal MR, Hunger SP, Smith MT, Grouse V, Ma X, Buffler PA, Pine SR. Site-specific translocation and evidence of postnatal origin of the t(1;19) E2A-PBX1 fusion in childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2002; 99:15101-6.
19. Cayuela JM, Gardie B, Sigaux F. Disruption of the multiple tumor suppressor gene MTS1/p16(INK4a)/CDKN2 by illegitimate V(D)J recombinase activity in T-cell acute lymphoblastic leukemias. Blood 1997; 90:3720-6.
20. Sakata J, Inoue J, Ohi H, Kosugi-Okano H, Mishima Y, Hatakeyama K, Niwa O, Kominami R. Involvement of V(D)J recombinase in the generation of intragenic deletions in the Rit1/Bcl11b tumor suppressor gene in gamma-ray-induced thymic lymphomas and in normal thymus of the mouse. Carcinogenesis 2004; 25:1069-75.
21. Aplan PD, Lombardi DP, Ginsberg AM, Cossman J, Bertness VL, Kirsch IR. Disruption of the human SCL locus by "illegitimate" V-(D)-J recombinase activity. Science 1990; 250:1426-9.
22. Brown L, Cheng JT, Chen Q, Siciliano MJ, Crist W, Buchanan G, Baer R. Site-specific recombination of the tal-1 gene is a common occurrence in human T cell leukemia. Embo J 1990; 9:3343-51.
23. Begley CG, Green AR. The SCL gene: From case report to critical hematopoietic regulator. Blood 1999; 93:2760-70.
24. Tsuji H, Ishii-Ohba H, Katsube T, Ukai H, Aizawa S, Doi M, Hioki K, Ogiu T. Involvement of illegitimate V(D)J recombination or microhomology-mediated nonhomologous end-joining in the formation of intragenic deletions of the Notch1 gene in mouse thymic lymphomas. Cancer Res 2004; 64:8882-90.
25. Lin YW, Nichols RA, Letterio JJ, Aplan PD. Notch1 mutations are important for leukemic transformation in murine models of precursor-T leukemia/lymphoma. Blood 2005.
26. O'Neil J, Calvo J, McKenna K, Krishnamoorthy V, Aster JC, Bassing CH, Alt FW, Kelliher M, Look AT. Activating Notch1 mutations in mouse models of T-ALL. Blood 2006; 107:781-5.
27. Weng AP, Ferrando AA, Lee W, Morris JPt, Silverman LB, Sanchez-Irizarry C, Blacklow SC, Look AT, Aster JC. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306:269-71.
28. Barreto V, Marques R, Demengeot J. Early death and severe lymphopenia caused by ubiquitous expression of the Rag1 and Rag2 genes in mice. Eur J Immunol 2001; 31:3763-72.
29. Wayne J, Suh H, Sokol KA, Petrie HT, Witmer-Pack M, Edelhoff S, Disteche CM, Nussenzweig MC. TCR selection and allelic exclusion in RAG transgenic mice that exhibit abnormal T cell localization in lymph nodes and lymphatics. J Immunol 1994; 153:5491-502.
30. Gladdy RA, Taylor MD, Williams CJ, Grandal I, Karaskova J, Squire JA, Rutka JT, Guidos CJ, Danska JS. The RAG-1/2 endonuclease causes genomic instability and controls CNS complications of lymphoblastic leukemia in p53/Prkdc-deficient mice. Cancer Cell 2003; 3:37-50.
31. Zhu C, Mills KD, Ferguson DO, Lee C, Manis J, Fleming J, Gao Y, Morton CC, Alt FW. Unrepaired DNA breaks in p53-deficient cells lead to oncogenic gene amplification subsequent to translocations. Cell 2002; 109:811-21.
32. Vanasse GJ, Halbrook J, Thomas S, Burgess A, Hoekstra MF, Disteche CM, Willerford DM. Genetic pathway to recurrent chromosome translocations in murine lymphoma involves V(D)J recombinase. J Clin Invest 1999; 103:1669-75.
33. Williams B, Lustig AJ. The paradoxical relationship between NHEJ and telomeric fusion. Mol Cell 2003; 11:1125-6.
34. Haines BB, Ryu CJ, Chang S, Protopopov A, Luch A, Kang YH, Draganov DD, Fragoso MF, Paik SG, Hong HJ, Depinho RA, Chen J. Block of T cell development in p53-deficient mice accelerates development of lymphomas with characteristic RAG-dependent cytogenetic alterations. Cancer Cell 2006; 9:109-20.
35. Bories JC, Demengeot J, Davidson L, Alt FW. Gene-targeted deletion and replacement mutations of the T-cell receptor beta-chain enhancer: The role of enhancer elements in controlling V(D)J recombination accessibility. Proc Natl Acad Sci USA 1996; 93:7871-6.
36. Bouvier G, Watrin F, Naspetti M, Verthuy C, Naquet P, Ferrier P. Deletion of the mouse T-cell receptor beta gene enhancer blocks alphabeta T-cell development. Proc Natl Acad Sci USA 1996; 93:7877-81.
37. Ryu CJ, Haines BB, Draganov DD, Kang YH, Whitehurst CE, Schmidt T, Hong HJ, Chen J. The T cell receptor beta enhancer promotes access and pairing of Dbeta, and Jbeta gene segments during V(D)J recombination. Proc Natl Acad Sci USA 2003; 100:13465-70.
38. Liao MJ, Zhang XX, Hill R, Gao J, Qumsiyeh MB, Nichols W, Van Dyke T. No requirement for V(D)J recombination in p53-deficient thymic lymphoma. Mol Cell Biol 1998; 18:3495-501.
39. Nacht M, Jacks T. V(D)J recombination is not required for the development of lymphoma in p53-deficient mice. Cell Growth Differ 1998; 9:131-8.
40. Difilippantonio MJ, Zhu J, Chen HT, Meffre E, Nussenzweig MC, Max EE, Ried T, Nussenzweig A. DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation. Nature 2000; 404:510-4.
41. Liu G, Parant JM, Lang G, Chau P, Chavez-Reyes A, El-Naggar AK, Multani A, Chang S, Lozano G. Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet 2004; 36:63-8.
42. Greaves MF, Wiemels J. Origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer 2003; 3:639-49.
43. Monni O, Knuutila S. 11q deletions in hematological malignancies. Leuk Lymphoma 2001; 40:259-66.
44. Tanaka K, Eguchi M, Eguchi-Ishimae M, Hasegawa A, Ohgami A, Kikuchi M, Kyo T, Asaoku H, Dohy H, Kamada N. Restricted chromosome breakpoint sites on 11q22-q23.1 and 11q25 in various hematological malignancies without MLL/ALL-1 gene rearrangement. Cancer Genet Cytogenet 2001; 124:27-35.
45. Bassing CH, Suh H, Ferguson DO, Chua KF, Manis J, Eckersdorff M, Gleason M, Bronson R, Lee C, Alt FW. Histone H2AX: A dosage-dependent suppressor of oncogenic translocations and tumors. Cell 2003; 114:359-70.
46. Celeste A, Petersen S, Romanienko PJ, Fernandez-Capetillo O, Chen HT, Sedelnikova OA, Reina-San-Martin B, Coppola V, Meffre E, Difilippantonio MJ, Redon C, Pilch DR, Olaru A, Eckhaus M, Camerini-Otero RD, Tessarollo L, Livak F, Manova K, Bonner WM, Nussenzweig MC, Nussenzweig A. Genomic instability in mice lacking histone H2AX. Science 2002; 296:922-7.
47. Oikawa T, Yamada T. Molecular biology of the Ets family of transcription factors. Gene 2003; 303:11-34.
48. Stilgenbauer S, Schaffner C, Litterst A, Liebisch P, Gilad S, Bar-Shira A, James MR, Lichter P, Dohner H. Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. Nat Med 1997; 3:1155-9.
49. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B, Reed JC. Tumor suppressor p53 is a regulator of bcl-2 and box gene expression in vitro and in vivo. Oncogene 1994; 9:1799-805.
50. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75:817-25.
51. Tarapore P, Horn HF, Tokuyama Y, Fukasawa K. Direct regulation pf the centrosome duplication cycle by the p53-p21 Waf1/Cip1 pathway. Oncogene 2001; 20:3173-84.
52. Mombaerts P, Terhorst C, Jacks T, Tonegawa S, Sancho J. Characterization of immature thymocyte lines derived from T-cell receptor or recombination activating gene 1 and p53 double mutant mice. Proc Natl Acad Sci USA 1995; 92:7420-4.
53. Rothenberg EV, Taghon T. Molecular genetics of T cell development. Annu Rev Immunol 2005; 23:601-49.
54. Danska JS, Holland DP, Mariathasan S, Williams KM, Guidos CJ. Biochemical and genetic defects in the DNA-dependent protein kinase in murine scid lymphocytes. Mol Cell Biol 1996; 16:5507-17.